Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From OpGen, Inc.
The combination of the molecular diagnostic companies is structured as an acquisition of Curetis by OpGen. The merged companies will be a based in the US.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced July 2017.
Recent regulatory events and dealmaking highlight an increase in the pace of innovation in rapid infectious disease testing.
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
- Research, Analytical Equipment & Supplies
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- AdvanDx, Inc.
- AdvanDx A/S, Curetis N.V.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.